Actively Recruiting
Study of Docetaxel, Carboplatin with Inetetamab and Pyrotinib for Treating Locally Advanced HER2-Positive Breast Cancer in Adult Women
Led by Wang Ouchen · Updated on 2024-01-31
154
Participants Needed
1
Research Sites
313 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the use of a combination of docetaxel, carboplatin, Inetetamab, and Pyrotinib as a preoperative treatment for locally advanced HER2-positive breast cancer in women. This prospective, open, multi-center, single-arm trial aims to assess the treatments effectiveness by focusing on total pathological complete response tpCR after surgery. The study also monitors long-term outcomes such as event-free survival, disease-free survival, distant metastasis-free survival, overall survival, and central nervous system disease-free survival. Additionally, the trial explores biomarkers related to treatment efficacy and evaluates the cardiotoxicity of Inetetamab and Pyrotinib.
CONDITIONS
Brief Title
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
